Literature DB >> 14985703

Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2.

Valérie Benoit1, Biserka Relic, Xavier de Leval Xd, Alain Chariot, Marie-Paule Merville, Vincent Bours.   

Abstract

The oncoprotein HER-2/neu is a prosurvival factor and its overexpression has been correlated with adverse prognosis in breast cancers. High levels of the cyclooxygenase-2 (COX-2), a proinflammatory and antiapoptotic enzyme, were detected in HER-2-positive tumors and this observation was linked to an HER-2-mediated induction of COX-2 gene transcription. Here, we report that COX-2 expression, and synthesis of its major enzymatic product, PGE2, leads in turn to an enhanced HER-2 expression. Moreover, COX-2 enzymatic inhibition dramatically reduced HER-2 protein levels, efficiently increased the cancer cells sensitility to chemotherapeutic treatment and acted in synergy with HER-2 inhibitor, trastuzumab. Therefore, we propose an original model where HER-2 and COX-2 transcriptionally regulate each other in a positive loop.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985703     DOI: 10.1038/sj.onc.1207295

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  27 in total

1.  Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype.

Authors:  Theodore M Brasky; Matthew R Bonner; Kirsten B Moysich; Christine B Ambrosone; Jing Nie; Meng Hua Tao; Stephen B Edge; Bhaskar V S Kallakury; Catalin Marian; David S Goerlitz; Maurizio Trevisan; Peter G Shields; Jo L Freudenheim
Journal:  Cancer Causes Control       Date:  2011-04-23       Impact factor: 2.506

Review 2.  Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.

Authors:  J C Becker; C Muller-Tidow; H Serve; W Domschke; T Pohle
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

Review 3.  The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives.

Authors:  Demetrios Moris; Michalis Kontos; Eleftherios Spartalis; Ian S Fentiman
Journal:  Breast Care (Basel)       Date:  2016-10-24       Impact factor: 2.860

4.  Interaction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: A new field for prevention and treatment.

Authors:  Giuliana Cássia Morrone Taromaru; Vilmar Marques DE Oliveira; Maria Antonieta Longo Galvão Silva; Wagner Ricardo Montor; Fabio Bagnoli; José Francisco Rinaldi; Tsutomu Aoki
Journal:  Oncol Lett       Date:  2011-12-21       Impact factor: 2.967

Review 5.  Role of the progesterone receptor (PR) in the regulation of inflammatory response pathways and aromatase in the breast.

Authors:  Carole R Mendelson; Daniel B Hardy
Journal:  J Steroid Biochem Mol Biol       Date:  2006-10-17       Impact factor: 4.292

6.  Analysis of promoters and expression-targeted gene therapy optimization based on doubling time and transfectability.

Authors:  Georgina L Dobek; Xiujuan Zhang; Daniel A Balazs; W T Godbey
Journal:  FASEB J       Date:  2011-05-20       Impact factor: 5.191

Review 7.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

8.  The inhibition of early stages of HER-2/neu-mediated mammary carcinogenesis by dietary n-3 PUFAs.

Authors:  Lisa D Yee; Deepak Agarwal; Thomas J Rosol; Amy Lehman; Min Tian; Jennifer Hatton; Jessica Heestand; Martha A Belury; Steven K Clinton
Journal:  Mol Nutr Food Res       Date:  2012-12-05       Impact factor: 5.914

Review 9.  Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

Authors:  Alphonse-E Sirica
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

10.  Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms.

Authors:  Daniel B Hardy; Bethany A Janowski; Chien-Cheng Chen; Carole R Mendelson
Journal:  Mol Endocrinol       Date:  2008-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.